Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT01187654

Bone Marrow Derived AC 133+ and Mono-Nuclear Cells (MNC) Implantation in Myocardial Infarction (MI) Patient

Comparison the Therapeutic Outcomes of Bone Marrow Derived AC 133+ and Mono-Nuclear Cells (MNC) Implantation in Patient With Acute Myocardial Infarction Underwent PCI Procedure

Sponsor: Royan Institute

Conditions Myocardial Infarction

Interventions AC133 CONTROL MNC

Updated 6 times since 2017 Last updated: Dec 25, 2012 Started: May 31, 2009 Primary completion: Sep 30, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01187654, this PHASE2/PHASE3 trial focuses on Myocardial Infarction and remains completed. Sponsored by Royan Institute, it has been updated 6 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Royan Institute

Data source: Royan Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tehran, Iran